Data-driven
precision medicine
Bringing the power of data and artificial intelligence to healthcare
With the power of AI, we now have the ability to
-
ACCELERATE
the discovery of novel targets
-
PREDICT
the effectiveness of treatments
-
IDENTIFY
potentially life-saving clinical trials
-
DIAGNOSE
multiple diseases earlier
Explore Tempus
We can assist pharmaceutical and biotech companies with better drug development.
Learn MoreWe have built a proprietary Platform to make data accessible and deploy AI at scale.
Learn MoreOur Science
Through our scientific publications and research projects, we are accelerating and transforming personalized patient care.
View All Publications
Nature Biotechnology Study Reveals that Tempus’ xT Platform Increases Cancer Patients’ Personalized Therapeutic Opportunities
Extensive molecular profiling combined with clinical data identifies targeted therapies and clinical trials for a large proportion of cancer patients, and paired tumor/normal plus transcriptome sequencing outperforms tumor-only DNA panel testing.
A Pan-cancer Organoid Platform for Precision Medicine
Showcasing a robust pan-cancer tumor organoid (TO) platform, revealing genomic/transcriptome fidelity of TO culture from >1,000 patients. We demonstrate a neural-network-based high-throughput approach for label-free, light-microscopy-based drug assays capable of predicting patient-specific heterogeneity in drug responses with applicability across solid cancers.
Validation of a Liquid Biopsy Assay with Molecular and Clinical Profiling of Circulating Tumor DNA
Actionable variants would have been missed if only solid tumor or liquid biopsy tests were performed. Thus, we believe that liquid biopsies provide value to patients when used in combination with standard tissue genotyping.
Improving patient care through high quality testing, clinical trial matching, and deep research data that powers scientific discovery
Tempus Announces Agreement With the U.S. Department of Veterans Affairs National Precision Oncology Program
The VA’s National Precision Oncology Program is collaborating with Tempus to expand access to its portfolio of sequencing offerings to support physicians in delivering personalized care for their patients with cancer.
READ ARTICLETempus and Geisinger Find ECG-Based AI Model Can Predict Undiagnosed Structural Heart Disease
The rECHOmmend study, published in Circulation, demonstrated a novel machine learning model that uses data from a 12-lead ECG to identify patients at high risk of undiagnosed SHD.
READ PRESS RELEASETempus Founder & CEO Op-Ed “We need health data banks not unlike what we have for organ donors”
Eric Lefkofsky discusses how de-identified data can enable doctors and researchers to learn from the experience of today’s patients to help tomorrow’s.
READ PRESS RELEASEThis is data-driven precision medicine
This is the future of healthcare.